EUVIMEDEUVIMED entdecken
Open Access

Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials

David Roofeh iD, Oliver Distler, Yannick Allanore, Christopher P Denton iD, Dinesh Khanna

Journal of Scleroderma and Related Disorders · 2020-03 · 5 (2_suppl) · 61-71

DOI: 10.1177/2397198320903208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 05.03.2020. Verfasst von David Roofeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Scleroderma Program, University of Michigan, Ann Arbor, MI, USA. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic sclerosis–associated interstitial lung disease remains a leading cause of mortality. Despite decades of clinical trials, the treatment effects of disease modifying anti-rheumatic drugs continue to be modest and there remains a great need for therapies that attenuate and hopefully ameliorate parenchymal lung disease. In this review, we highlight the key clinical trials that have shaped the management strategies employed by the authors, providing their strength of recommendation based on level of evidence. We also review lessons learned in more recent years, suggesting a benefit in targeting patients with subclinical interstitial lung disease with high risk for progression early in the disease course, as well as the benefit seen in a large clinical trial leading to the first Food and Drug Administration–approved treatment for systemic sclerosis–associated interstitial lung disease. These lessons come in a context of heterogeneity of patient populations and response to therapy, as well as the inherent constraints of time-limited studies to detect meaningful outcomes for patients.

Schlagwörter

Stichwörter der Autor:innen

Systemic sclerosisclinical trialsinterstitial lung diseasemanagementtreatment

Autor:innen und Institutionen

  • Scleroderma Program, University of Michigan, Ann Arbor, MI, USA.
  • Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Rheumatology A, Cochin Hospital, Paris Descartes University, Paris, France.
  • Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK.
  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: David Roofeh, Christopher P Denton

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Roofeh, D., Distler, O., Allanore, Y., Denton, C. P., & Khanna, D. (2020). Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 5(2_suppl), 61-71. https://doi.org/10.1177/2397198320903208

Vancouver

Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020;5(2_suppl):61-71. doi:10.1177/2397198320903208

BibTeX
@article{Roofeh2020,
  author = {Roofeh, David and Distler, Oliver and Allanore, Yannick and Denton, Christopher P and Khanna, Dinesh},
  title = {Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials},
  journal = {Journal of Scleroderma and Related Disorders},
  year = {2020},
  volume = {5},
  number = {2_suppl},
  pages = {61--71},
  doi = {10.1177/2397198320903208}
}
Kostenlos starten →